Accessibility Menu
NewAmsterdam Pharma logo

NewAmsterdam Pharma(NASDAQ) NAMS

Current Price$32.31
Market Cap$3.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+199%
5 Year+233%
1 Year+43%
1 Month+8%
NewAmsterdam Pharma last closing stock price
MetricPriceDate
Last closeUSD 32.342026-07-21
NewAmsterdam Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.85%USD 33.292026-07-14
1 month+8.41%USD 29.832026-06-18
3 month+1.25%USD 31.942026-04-22
Year to date-7.81%USD 35.082025-12-31
1 year+43.35%USD 22.562025-07-21
3 year+175.23%USD 11.752023-07-21
5 year+233.4%USD 9.702021-07-22
Since inception+199.45%USD 10.802021-02-08

NewAmsterdam Pharma Financials at a Glance

Market Cap

$3.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$22.57M

Net Income (TTM)

-$212.73M

EPS (TTM)

-$1.80

P/E Ratio

-17.92

Dividend

$0.00

Beta (Volatility)

0.52 (Low)

Price

$32.31

Volume

35,078

Open

$30.23

Previous Close

$32.31

Daily Range

$29.68 - $32.49

52-Week Range

$21.14 - $42.21

Estimated Earnings Date

Aug 5, 2026

NAMS News

Foolcom-Featured.png

NewAmsterdam (NAMS) Q2 Revenue Jumps 49%

Motley Fool Markets TeamAug 6, 2025
Doctor with senior man_GettyImages-1147479334

Why Shares of NewAmsterdam Pharma Were Plummeting on Wednesday

James HalleyJun 7, 2023

NAMS: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NewAmsterdam Pharma

NewAmsterdam Pharma makes oral pills for people with high cholesterol. These treatments help patients who cannot use current medicines. The company focuses on diseases that affect heart health.

Fighting Cholesterol with Oral Pills

  • Obicetrapib Monotherapy: Oral treatment designed to lower low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, while raising good cholesterol.
  • Fixed-Dose Combination: Single pill combining two medicines for patients needing more help to lower cholesterol.
  • Supply Revenue: Income from selling drug ingredients and finished tablets to international partners; accounted for 100% of revenue in Q1 2026.

Partnerships and Growth Steps

  • Entered a supply agreement in August 2025 with A. Menarini International Licensing S.A. to provide tablets for European markets.
  • Received acceptance from the European Medicines Agency in August 2025 for reviews of its new cholesterol treatments.
  • Completed a public stock offering in December 2024 that raised $453.4 million in net proceeds for clinical development.
  • Signed an exclusive license agreement with Menarini in June 2022 to commercialize treatments in most European countries.

The Benefits of Oral Care

NewAmsterdam Pharma uses a specific method to block the Cholesteryl Ester Transfer Protein (CETP), which helps manage how cholesterol moves in the blood. This oral pill approach offers an alternative for the millions of patients who prefer daily tablets over injectable therapies.

Revenue and Spending Trends

  • Revenue reached $3.0 million in Q1 2026, representing a 2.1% increase from Q1 2025.
  • Operating loss was $-58.4 million in Q1 2026, which improved from a loss of $-68.9 million in Q1 2025.
  • Net loss reached $-48.4 million in Q1 2026, which worsened from $-39.5 million in Q1 2025.
  • Free cash flow was $-30.6 million in Q1 2026, an improvement from $-36.5 million in Q1 2025.

Bottom Line

NewAmsterdam Pharma has transitioned from a research-focused entity to a late-stage developer with significant international partnerships. Its focus on oral alternatives for heart health diseases has driven its recent clinical and financial expansion.

AI Generated • May 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

100

CEO

Michael H. Davidson, MD

Website

www.newamsterdampharma.com

Headquarters

Naarden, NH 1411 DC, NL

NAMS Financials

Key Financial Metrics (TTM)

Gross Margin

97.52%

Operating Margin

-953.59%

Net Income Margin

-942.76%

Return on Equity

-29.80%

Return on Capital

-33.01%

Return on Assets

-29.04%

Earnings Yield

-5.58%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

116.90M

Volume

35.08K

Avg. Volume

1.31M

Financials (TTM)

Gross Profit

$22.01M

Operating Income

-$215.18M

EBITDA

-$212.50M

Operating Cash Flow

-$141.92M

Capital Expenditure

-$268.00K

Free Cash Flow

-$142.19M

Cash & ST Invst.

$636.11M

Total Debt

$23.00K

NewAmsterdam Pharma Performance Analysis

NewAmsterdam Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 102,694,000N/A
20232023-12-31USD 14,090,000-86.3%
20242024-12-31USD 45,563,000223.4%
20252025-12-31USD 22,503,000-50.6%
NewAmsterdam Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30542.9%
Q32025-09-30-98.2%
Q42025-12-31-90.8%
Q12026-03-319400.0%
NewAmsterdam Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.19-14.8%
20232023-12-31USD -2.1580.5%
20242024-12-31USD -2.5618.9%
20252025-12-31USD -1.72-32.8%
NewAmsterdam Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3055.9%
Q32025-09-30-306.7%
Q42025-12-31-6.6%
Q12026-03-3138.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$3.04M

+2.1%

Gross Profit

$2.54M

-14.7%

Gross Margin

83.55%

N/A

Market Cap

$3.78BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$37.81M

N/A

Employees

100

N/A

Net Income

-$48.44M

-22.6%

EBITDA

-$48.38M

-22.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$636.11M

-21.3%

Total Debt

$23.00K

-94.1%

Accounts Receivable

$8.22M

+409.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$23.00K

-90.9%

Return on Assets

-29.04%

N/A

Return on Invested Capital

-32.35%

N/A

Free Cash Flow

-$30.64M

+16.0%

Operating Cash Flow

-$30.60M

+16.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VKTXViking Therapeutics, Inc.
$37.95+4.32%
AKROAkero Therapeutics, Inc.
$54.65+0.00%
SLNOSoleno Therapeutics, Inc.
$53.01+0.00%
LGNDLigand Pharmaceuticals Incorporated
$305.47+3.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$207.54+0.02%
INTCIntel
$105.54+0.09%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.14+0.24%
SPCXSpace Exploration Technologies
$123.67+0.03%

Questions About NAMS

What is the current price of NewAmsterdam Pharma?

NewAmsterdam Pharma is trading at $32.31 per share.

What is the 52-week range for NewAmsterdam Pharma?

Over the past 52 weeks, NewAmsterdam Pharma has traded between $21.14 and $42.21.

How much debt does NewAmsterdam Pharma have?

As of the most recent reporting period, NewAmsterdam Pharma reported total debt of $23.00K.

How much cash does NewAmsterdam Pharma have on hand?

NewAmsterdam Pharma reported $458.94M in cash and cash equivalents in its most recent financial results.

What is NewAmsterdam Pharma’s dividend yield?

NewAmsterdam Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services